Here is a recent research study that provides more evidence on the benefits of including T3 in thyroid replacement therapy. One of the authors is a previous president of the American Thyroid Association, Professor Antonio Bianco.
Professor Bianco’s statement on the research study is: “These results were obtained through the analysis of 1.26 million patients with hypothyroidism, seen in 126 health organizations across 17 countries. Over a 20-year follow-up, patients receiving combination therapy (LT4+LT3 or DTE) had 27% lower risk of dementia and 31% lower risk of mortality. These results should reset the approach to the treatment of hypothyroidism”.
It will be interesting to see whether the endocrinology community pay any attention. I can imagine that many of them will choose to dismiss the findings. However, as time goes on, the evidence for many thyroid patients benefitting from T3, is mounting.
Here is the abstract:
“Treatment of Hypothyroidism that Contains Liothyronine is Associated with Reduced Risk of Dementia and Mortality”
Fabyan Esberard de Lima Beltrao, Antonio Bianco et al.
June 2025, The Journal of Clinical Endocrinology & Metabolism, dgaf367.
URL: https://doi.org/10.1210/clinem/dgaf367
Note: I will update this blog post when the full article becomes available.
Best wishes, Paul
